Telemedicine company Musely has secured more than $360 million in non-dilutive capital from General Catalyst's Customer Value Fund, a financing structure that lets the company scale aggressively without handing over equity to investors.
The deal, reported by TechCrunch, is worth paying attention to even if you have never used Musely's skin, hair, or menopause care services. What it actually demonstrates is something more interesting than a healthcare funding round: a major venture firm has packaged predictable consumer spending into a financing product, and it is starting to look like a template other consumer startups will want to copy.
Musely operates as a direct-to-consumer telemedicine platform, meaning its revenue model depends heavily on repeat customers who come back regularly for prescription skincare, hair loss treatment, and hormonal care. That kind of recurring, measurable spend is exactly what makes revenue-linked financing attractive. Lenders, or in this case General Catalyst through its Customer Value Fund, can model the expected lifetime value of existing customers with reasonable confidence, then advance capital against that stream without requiring equity in return. The company gets its growth funding. The investor gets repaid from future revenue. No dilution, no new shareholders, no valuation negotiation.
Musely says it will deploy the capital toward customer acquisition, which is the highest-cost line item for almost every direct-to-consumer company operating at scale. Paid social, search advertising, influencer partnerships, and clinical credibility campaigns are all expensive. The economics only work if customers stay long enough and spend enough to justify the upfront cost of acquiring them. Musely's apparent argument to General Catalyst is that its customers do exactly that, and the fund agreed to the tune of $360 million.
The timing is not coincidental. The IPO market for consumer and healthcare startups has been difficult for the better part of three years. Venture rounds at high valuations are harder to justify when public market comparables have compressed. Founders who raised at peak 2021 valuations are reluctant to take down rounds at lower prices, both for the dilution it causes and for the signal it sends to the market. Non-dilutive capital sidesteps that entire conversation.
General Catalyst's Customer Value Fund is one of the more sophisticated versions of this concept currently operating. Rather than structuring deals as simple revenue-based financing, which has existed in various forms for decades through companies like Clearco and Lighter Capital, General Catalyst is applying institutional-scale underwriting to consumer lifetime value as an asset class. The fund essentially asks: if we can quantify how much a customer cohort will spend over the next three to five years with reasonable accuracy, can we build a lending product around that projection? For subscription-adjacent businesses with strong retention data, the answer appears to be yes.
This matters for the broader startup ecosystem because it creates a third path that did not really exist at scale before. Founders have historically chosen between venture capital, which is expensive in equity terms but patient in repayment, and traditional debt, which preserves equity but demands collateral and often does not fit early or growth-stage company profiles. Revenue-linked capital from a fund like General Catalyst sits in between: repaid from operations, structured around business performance, and available without surrendering board seats or ownership percentages.
The consumer health angle is worth watching separately
Musely's specific market also deserves attention on its own terms. Direct-to-consumer telehealth for dermatology, hair loss, and menopause care sits at the intersection of several durable trends. Consumers have grown increasingly comfortable with remote medical consultations. Prescription treatments for conditions that were historically underserved, particularly for women, are now accessible online without in-person clinic visits. And subscription-style adherence to ongoing treatment creates exactly the kind of lifetime value that makes the General Catalyst financing model work.
The menopause care segment in particular has seen a notable increase in both consumer demand and investor attention over the past two years, as companies recognized a large and historically underfunded patient population. Musely's inclusion of that category alongside skincare and hair treatments suggests the company is positioning itself as a broader women's health platform rather than a single-condition provider, which meaningfully expands its addressable market and reduces churn risk by increasing the number of reasons a customer might stay.
For founders watching this deal, the practical takeaway is straightforward. If your business has measurable customer retention, consistent repeat purchase behavior, and a customer acquisition model that produces predictable cohort economics, you now have more financing options than the traditional venture fundraising calendar allows. General Catalyst's Customer Value Fund is not the only player in this space, but a $360 million deployment into a single company signals that the category is maturing fast. Expect more funds to build similar products, and expect more consumer and healthcare startups to use them as the IPO window remains uncertain through the rest of 2026.
Also read: Fun raises $72 million to build the payment rails that make crypto transactions feel like normal fintech • Founders Fund closes its largest fund ever at $6 billion with Peter Thiel and senior staff putting in $1.5 billion themselves • OPay hires Citigroup JPMorgan and Deutsche Bank as it targets a $4 billion US IPO later this year
